https://images.financialexpress.com/2020/04/1-1062.jpg
The spread of the coronavirus pandemic derailed Dabur’s growth trajectory in the fourth quarter of 2019-20.

Chyawanprash sales jump 4 times due to coronavirus, says Dabur; key takeaways from Q4 results

As the coronavirus pandemic hit billions of lives, consumers’ renewed focus on immunity boosting and healthcare brands has led to FMCG major Dabur witnessing an exponential growth in the sales of its chyawanprash range.

by

As the coronavirus pandemic hit billions of lives, consumers’ renewed focus on immunity boosting and healthcare brands has led to FMCG major Dabur witnessing an exponential growth in the sales of its chyawanprash range. “Demand patterns have changed significantly, with consumers increasingly seeking Ayurveda-based interventions for boosting their immunity… We are already witnessing a 400% surge in demand for our flagship immunity booster Dabur Chyawanprash and an 80% growth in Dabur Honey,” Mohit Malhotra, Chief Executive Officer, Dabur India Ltd, said. The company has also released its Q4 and full-year results on wednesday.

Key takeaways from Dabur results

While Dabur was on track to post a positive growth, the nationwide lockdown has impacted its business with the company’s portfolio mostly comprising non-essential categories. However, the company decided to launch new products which are in line with the “changing demand patterns”. This includes items in preventive healthcare and personal hygiene such as Dabur Tulsi Drops, Dabur Amla Juice, Dabur Giloy-Neem-Tulsi juice and Dabur Immunity Kit etc. Dabur also debuted in the hand sanitizer category during lockdown as demand shot up.